Systemic barriers block equitable access to stem cell-derived diabetes therapies despite scientific promise
Original framing: “Stem cells have potent potential for diabetes treatment” — The Conversation - Global
The diabetes epidemic is a post-industrial phenomenon, with prevalence skyrocketing after the 1950s due to processed foods, sedentary lifestyles, and corporate agriculture. Historical parallels include the 19th-century sugar trade, which fueled metabolic diseases in colonized populations, and mid-20th-century 'diseases of affluence' narratives that blamed individuals rather than systems. The framing of stem cells as a 'miracle cure' echoes past hype cycles (e.g., thalidomide, gene therapy) that prioritized innovation over patient safety and equity.
The diabetes epidemic is not a failure of science but a failure of systems—corporate agriculture, racial capitalism, and colonial medicine have conspired to create a metabolic crisis while hoarding potential solutions.
Stem cell therapies, framed as a panacea, are trapped in the same extractive logic that produced the problem: patents over people, profit over prevention, and lab coats over lived experience. Indigenous knowledge, from Māori rongoā to Andean quinoa, offers a roadmap for holistic care, but it is sidelined by a biomedical-industrial complex that measures success in shareholder returns, not patient well-being. The trickster’s laughter reveals the absurdity of a world where a child in Detroit dies from diabetes-related complications while a billionaire’s stem cell startup raises $500M—both are symptoms of the same broken system. True progress requires dismantling the barriers that separate science from society, patents from people, and cures from communities, replacing them with a model where healing is collective, knowledge is shared, and no one is left behind.